Low-density lipoprotein

Webinars/Videos

  • Running time: 58 minutes, 46 seconds

     

    01.28 Concept of cumulated LDL exposure (mg-years)

    05.11 Re-defining secondary prevention

    08.04 Early secondary prevention

    11.27 Late secondary prevention (CHD)

    19.17 Late secondary prevention (PAD)

    20.15 Very late secondary prevention (ACS)

    23.18 Longer is better

    24.55 Earlier is better

    26.21 Younger is better

    28.39 Older Adults also deserve treatment

    41.12 Audience Q&A

    Webinars/Videos

    “Lower, Longer, Sooner, Earlier, and Younger”: Do we have enough evidence?

    Prof. Chiang discusses Atherosclerotic Cardiovascular Disease (ASCVD) in context of cumulated LDL exposure, and the different stages of secondary prevention and how starting to manage the disease at a younger age or earlier stage is beneficial. At 41:12 he answers audience questions.

    View

  • Running time: 35 minutes, 49 seconds

     

    00.00 Patients and plaque

    03.30 Pictorial representation and
    primary prevention or adherence

    07.00 Calcium Scoring

    13.00 Other targets: Lp(a)

    21.00 Triglycerides

    28.00 Special: Latest data from ESC

    Webinars/Videos

    ASCVD Roundtable Part 2: Other targets and ESC 2023 Highlights

    In this second part of the Round Table conversation, the Editorial Panel discuss how showing patients’ images of their plaques help with adherence, discuss other targets such as Lp (a) and triglycerides and most importantly, discuss some of the latest data from the recently concluded ESC congress.

    View
View All Low-density lipoprotein Webinars/Videos

Infographics

View All Low-density lipoprotein Infographics

Articles

View All Low-density lipoprotein Articles

Case Studies

  • Case Studies

    Quiz of the month – August 2023

    Take this short quiz to test your knowledge on the recently published debate on dyslipidemias titled “Great debate: lipid-lowering therapies should be guided by vascular imaging rather than by circulating biomarkers”.

    CLICK HERE TO VIEW THE DEBATE.

    Eur Heart J. 2023 Jul 1;44(25):2292-2304. doi: 10.1093/eurheartj/ehad275

    Take

  • Case Studies

    Quiz of the month – April 2023

    Take our patient case study quiz specially curated for you by our Faculty Member, Prof. Samer Ellahham.

    Case Study: A 65-year-old man with a history of dyslipidemia, type 2 diabetes mellitus and systemic hypertension.

     

    Presentation:

    New onset crescendo angina x 5 days culminating

    Rest pain for the past 2h

    No history of other vascular events or heart attack, no TIA or stroke

    Weight: 90 kg

    Exam: BP 150/85 (slightly elevated), Heart Rate 80

    No murmur detected

     

    Medication:

    Valsartan 160 mg daily, Aspirin 81 mg daily, Rosuvastatin 10 mg daily, Metformin 500 mg twice daily

     

    Labs:

    BMI 31kg/m2, waist circumference 101.6 cm (40 inches), (-) tobacco (quit last year – 60-pack-year history)

    Normal CBC, electrolytes

    Troponin: Elevated

    Electrocardiogram:1-2 mm horizontal ST depression infero-lateral leads

    Chest X-ray: Normal

     

    Lipid panel:

    Total cholesterol (TC) 192 mg/dL

    HDL-C 46 mg/dL

    Triglycerides 180 mg/dL (non-fasting)

    LDL-C 110 mg/dL

    Non-HDL-C 146 mg/ dL

     

    What are the first impressions about this patient?

    Take

  • Case Studies

    Case Study – December 2022

    Our patient case study specially curated for you by our Faculty Member, Prof. Samer Ellahham on concerns about statin associated Diabetes Mellitus.

    Case Study: RS is a 64-year-old Male having dyslipidemia.

     

    Vital parameters:

    BP 144/87 mm Hg

    Low-density lipoprotein cholesterol (LDL-C) 112 mg/dL

    High-density lipoprotein cholesterol (HDL-C) of 47 mg/dL

    Triglycerides 190 mg/dL

    (-) tobacco, (-) alcohol

    Body mass index (BMI) 33 kg/m2

     

    Medication:

    Valsartan 80 mg/d

     

    Family history:

    Father developed type 2 diabetes mellitus (T2DM) and ASCVD at age 58

     

    Labs:

    Fasting blood glucose 103 mg/dL

    HbA1C 5.8%

    Serum Creatinine 1.1 mg/dL

    Urinary analysis within normal limits

     

     

    RS reports that he is reluctant to take statins as they cause diabetes especially with his family history.

    Read More
View All Low-density lipoprotein Case Studies